255 related articles for article (PubMed ID: 29206889)
1. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
Guihot A; Marcelin AG; Massiani MA; Samri A; Soulié C; Autran B; Spano JP
Ann Oncol; 2018 Feb; 29(2):517-518. PubMed ID: 29206889
[No Abstract] [Full Text] [Related]
2. Nivolumab in non-small-cell lung cancer with EGFR mutation.
Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
[No Abstract] [Full Text] [Related]
3. Nivolumab improves survival for patients with advanced lung cancer.
Printz C
Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
[No Abstract] [Full Text] [Related]
4. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
[No Abstract] [Full Text] [Related]
5. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
Funazo T; Nomizo T; Kim YH
J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
[No Abstract] [Full Text] [Related]
6. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.
Kimura H; Araya T; Yoneda T; Shirasaki H; Kurokawa K; Sakai T; Koba H; Tambo Y; Nishikawa S; Sone T; Kasahara K
Cancer Commun (Lond); 2019 Nov; 39(1):78. PubMed ID: 31753015
[No Abstract] [Full Text] [Related]
7. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.
Spano JP; Veyri M; Gobert A; Guihot A; Perré P; Kerjouan M; Brosseau S; Cloarec N; Montaudié H; Helissey C; Flament T; Gounant V; Lavolé A; Poizot-Martin I; Katlama C
AIDS; 2019 Sep; 33(11):F13-F19. PubMed ID: 31259762
[TBL] [Abstract][Full Text] [Related]
8. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
[No Abstract] [Full Text] [Related]
9. PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab.
Li P; Che G
Cancer Immunol Immunother; 2020 Mar; 69(3):489. PubMed ID: 31807877
[No Abstract] [Full Text] [Related]
10. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
11. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
Schouten RD; Muller M; de Gooijer CJ; Baas P; van den Heuvel M
Lung Cancer; 2018 Dec; 126():210-216. PubMed ID: 29179916
[No Abstract] [Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
[TBL] [Abstract][Full Text] [Related]
13. Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
Davis A; Mahar A; Wong K; Barnet M; Kao S
Clin Lung Cancer; 2021 Sep; 22(5):e665-e667. PubMed ID: 33349572
[No Abstract] [Full Text] [Related]
14. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
Roesel C; Kambartel K; Kopeika U; Berzins A; Voshaar T; Krbek T
Curr Oncol; 2019 Apr; 26(2):e270-e273. PubMed ID: 31043837
[TBL] [Abstract][Full Text] [Related]
15. Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab.
Senoo S; Ninomiya T; Makimoto G; Nishii K; Kano H; Watanabe H; Hata Y; Kubo T; Tanaka T; Hotta K; Maeda Y; Kiura K
Intern Med; 2019 Apr; 58(7):985-989. PubMed ID: 30568113
[TBL] [Abstract][Full Text] [Related]
16. ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer.
Nakazawa N; Yokobori T; Turtoi A; Shirabe K
Ann Surg Oncol; 2020 Mar; 27(3):943-944. PubMed ID: 31696394
[No Abstract] [Full Text] [Related]
17. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Osa A; Uenami T; Koyama S; Fujimoto K; Okuzaki D; Takimoto T; Hirata H; Yano Y; Yokota S; Kinehara Y; Naito Y; Otsuka T; Kanazu M; Kuroyama M; Hamaguchi M; Koba T; Futami Y; Ishijima M; Suga Y; Akazawa Y; Machiyama H; Iwahori K; Takamatsu H; Nagatomo I; Takeda Y; Kida H; Akbay EA; Hammerman PS; Wong KK; Dranoff G; Mori M; Kijima T; Kumanogoh A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282824
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
20. Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment.
Hirano S; Hayama N; Tabeta H; Kuroki T; Shiraishi Y; Fujita T; Amano H; Nakamura M; Shimizu S; Nakamura S
J Thorac Oncol; 2020 Jan; 15(1):e20-e22. PubMed ID: 31864556
[No Abstract] [Full Text] [Related]
[Next] [New Search]
